Evaluation of selenite effects on selenoproteins and cytokinome in human hepatoma cell lines

Molecules

Volumn 18, Issue 3, 2013, Pages 2549-2562

  Rusolo, Fabiola ^a   Pucci, Biagio ^a   Colonna, Giovanni ^b   Capone, Francesca ^a   Guerriero, Eliana ^a   Milone, Maria Rita ^a   Nazzaro, Melissa ^c   Volpe, Maria Grazia ^c   Di Bernardo, Gianni ^b   Castello, Giuseppe ^a   Costantini, Susan ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c CNR   (Italy)

Author keywords

Cytokines; GPX1; Hepatocarcinoma; HepG2; Huh7; Inflammation; Interactomics; SELENBP1; Selenite; SELK

Indexed keywords

CYTOKINE; GLUTATHIONE PEROXIDASE; GLUTATHIONE PEROXIDASE 1; SELENBP1 PROTEIN, HUMAN; SELENIUM BINDING PROTEIN; SELENOPROTEIN; SODIUM SELENITE;

ARTICLE; CELL STRAIN HEPG2; DRUG EFFECT; HUMAN; LIVER CELL; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; TUMOR CELL LINE;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYTOKINES; GLUTATHIONE PEROXIDASE; HEP G2 CELLS; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN INTERACTION MAPS; SELENIUM-BINDING PROTEINS; SELENOPROTEINS; SODIUM SELENITE;

EID: 84875615020     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules18032549     Document Type: Article

References (48)

1. Keshan Disease Research Group. Epidemiologic studies on the ethiologic relationship of selenium and Keshan disease. Chin. Med. J. 1979, 92, 477-482.
2. Sagara, Y.; Tan, S.; Maher, P.; Schubert, D. Mechanisms of resistance to oxidative stress in Alzheimer's diseases. Biofactors 1998, 8, 45-50.
3. Clark, L.C.; Combs, G.F., Jr.; Turnbull, B.W.; Slate, E.H.; Chalker, D.K.; Chow, J.; Davis, L.S.; Glover, R.A.; Graham, G.F.; Gross, E.G.; et al. Effects of Selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA 1996, 276, 1957-1963.
4. Rayman, M.P. Selenium in cancer prevention: A review of the evidence and mechanism of action. Proc. Nutr. Soc. 2005, 64, 527-542.
5. Peters, U.; Takata, Y. Selenium and the prevention of prostate and colorectal cancer. Mol. Nutr. Food Res. 2008, 52, 1261-1262.
6. Trottier, G.; Boström, P.J.; Lawrentschuk, N.; Fleshner, N.E. Nutraceuticals and prostate cancer prevention: A current review. Nat. Rev. Urol. 2009, 7, 21-30.
7. Yoo, M.H.; Xu, X.M.; Carlson, B.A.; Patterson, A.D.; Gladyshev, V.N.; Hatfield, D.L. Targeting thioredoxin reductase 1 reduction in cancer cells inhibits self-sufficient growth and DNA replication. PLoS One 2007, 2, e1112.
8. Lecomte, E.; Herberth, B.; Pirrollet, P.; Chancerelle, Y.; Arnaud, J.; Musse, N.; Paille, F.; Siest, G.; Artur, Y. Effect of alcohol comsumption on blood antioxidant nutrients and oxidative stress indicators. Am. J. Clin. Nutr. 1994, 60, 255-261.
9. Loguercio, C.; de Girolamo, V.; Federico, A.; Feng, S.L.; Cataldi, V.; del Vecchio Blanco, C.; Gialanella, G. Trace elements and chronic liver diseases, J. Trace Elem. Med. Biol. 1997, 11, 158-161.
10. Guarini, P.; Stanzial, A.M.; Olivieri, O.; Casaril, M.; Galvani, S.; Pantalena, M.; Corrocher, R. Erythrocyte membrane lipids and serum selenium in post-viral and alcoholic cirrhosis. Clin. Chim. Acta 1998, 270, 139-150.
11. Navarro-Alarcòn, M.; Lòpez-Martìnez, M.C. Essentiality of selenium in the human body: Relationship with different diseases. Sci. Total Environ. 2000, 249, 347-371.
12. Navarro-Alarcòn, M.; Lòpez-G de la Serrana, H.; Pèrez-Valero, V.; López-Martínez, M.C. Selenium concentrations in serum of individuals with liver diseases (cirrhosis or hepatitis): Relationships with some nutritional and biochemical markers. Sci. Total Environ. 2002, 291, 135-141.
13. Tashiro, H.; Kawamoto, T.; Okubo, T.; Koide, O. Variation in the distribution of trace elements in hepatoma. Biol. Trace Elem. Res. 2003, 95, 49-63.
14. Marra, M.; Sordelli, I.M.; Lombardi, A.; Lamberti, M.; Tarantino, L.; Giudice, A.; Stiuso, P.; Abbruzzese, A.; Sperlongano, R.; Accardo, M.; et al. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: An overview. J. Transl. Med. 2011, 9, 171.
15. Caraglia, M.; Giuberti, G.; Marra, M.; Addeo, R.; Montella, L.; Murolo, M.; Sperlongano, P.; Vincenzi, B.; Naviglio, S.; Prete, S.D.; et al. Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. Cell Death Dis. 2011, 2, e150.
16. Prete, S.D.; Montella, L.; Caraglia, M.; Maiorino, L.; Cennamo, G.; Montesarchio, V.; Piai, G.; Febbraro, A.; Tarantino, L.; Capasso, E.; et al. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: Multicenter phase II So.LAR. study. Cancer Chemother. Pharmacol. 2010, 66, 837-844.
17. Castello, G.; Scala, S.; Palmieri, G.; Curley, S.A.; Izzo, F. HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. Clin. Immunol. 2010, 134, 237-50.
18. Fusco, M.; Girardi, E.; Piselli, P.; Palombino, R.; Polesel, J.; Maione, C.; Scognamiglio, P.; Pisanti, F.A.; Solmone, M.; di Cicco, P.; et al. Collaborating Study Group, Epidemiology of viral hepatitis infections in an area of southern Italy with high incidence rates of liver cancer. Eur. J. Cancer 2008, 44, 847-53.
19. Colombino, M.; Sperlongano, P.; Izzo, F.; Tatangelo, F., Botti, G.; Lombardi, A.; Accardo, M.; Tarantino, L.; Sordelli, I.; Agresti, M.; et al. BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy. Cell Death Dis. 2012, 3, e259.
20. Bansal, M.P.; Mukhopadhyay, T.; Scott, J.; Cook, R.G.; Mukhopadhyay, R.; Medina, D. DNA sequencing of a mouse liver protein that binds selenium: Implications for selenium's mechanism of action in cancer prevention. Carcinogenesis 1990, 11, 2071-2073.
21. Chang, P.W.; Tsui, S.K.; Liew, C.; Lee, C.C.; Waye, M.M.; Fung, K.P. Isolation characterization and chromosomal mapping of a novel cDNA clone encoding human selenium binding protein. J. Cell. Biochem. 1997, 64, 217-224.
22. Raucci, R.; Colonna, G.; Guerriero, E.; Capone, F.; Accardo, M.; Castello, G.; Costantini, S. Structural and functional studies of the human selenium binding protein-1 and its involvment in hepatocellular carcinoma. Biochim. Biophys. Acta 2011, 1814, 513-522.
23. Di Stasio, M.; Volpe, M.G.; Colonna, G.; Nazzaro, M.; Polimeno, M.; Scala, S.; Castello, G.; Costantini, S. A possible predictive marker of progression for hepatocellular carcinoma. Oncol. Lett. 2011, 2, 1247-1251.
24. Lim, S.O.; Gu, J.M.; Kim, M.S.; Kim, H.S.; Park, Y.N.; Park, C.K.; Cho, J.W.; Park, Y.M.; Jung, G. Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: Methylation of the E-cadherin promoter. Gastroenterology 2008, 135, 2128-2140.
25. Kałuza, J.; Fijałkowski, P.; Krawczyk, P.; Błaszczyk, J.; Dworniak, D. Assessment of selected oxygen metabolism indexes in patients with chronic hepatitis C. Exp. Clin. Hepatol. 2008, 4, 7-11.
26. Du, S.; Zhou, J.; Jia, Y.; Huang, K. SelK is a novel ER stress-regulated protein and protects HepG2 cells from ER stress agent-induced apoptosis. Arch. Biochem. Biophys. 2010, 502, 137-143.
27. Huang, C.; Ding, G.; Gu, C.; Zhou, J.; Kuang, M.; Ji, Y.; He, Y.; Kondo, T.; Fan, J. Decreased Selenium-Binding Protein 1 Enhances Glutathione Peroxidase 1 Activity and Downregulates HIF-1α to Promote Hepatocellular Carcinoma Invasiveness. Clin. Cancer Res. 2012, 18, 3042-3053.
28. Pan, S.; Wang, Y.; Feng, L.; Fan, C.; Guo, D.; Liu, X.; Fan, J. Study on proteomics of Hela cell apoptosis in bufalin-induced human cervical carcinoma. Zhong Guo Zhong Yao Za Zhi 2012, 37, 1998-2004.
29. Baker, R.D.; Baker, S.S.; LaRosa, K.; Whitney, C.; Newburger, P.E. Selenium regulation of glutathione peroxidase in human hepatoma cell line Hep3B. Arch. Biochem. Biophys. 1993, 304, 53-57.
30. Fang, W.; Goldberg, M.L.; Pohl, N.M.; Bi, X.; Tong, C.; Xiong, B.; Koh, T.J.; Diamond, A.M.; Yang, W. Functional and physical interaction between the selenium-binding protein 1 (SBP1) and the glutathione peroxidase 1 selenoprotein. Carcinogenesis 2010, 31, 1360-1366.
31. Jabari, S.; Meissnitzer, M.; Quint, K.; Gahr, S.; Wissniowski, T.; Hahn, E.G.; Neureiter, D.; Ocker, M. Cellular plasticity of trans- and dedifferentiation markers in human hepatoma cellsin in vitro and in vivo. Int. J. Oncol. 2009, 35, 69-80.
32. Hussain, S.P.; Schwank, J.; Staib, F.; Wang, X.W.; Harris, C.C. TP53 mutations and hepatocellular carcinoma: Insights into the etiology and pathogenesis of liver cancer. Oncogene 2007, 26, 2166-2176.
33. Costantini, S.; Capone, F.; Guerriero, E.; Maio, P.; Colonna, G.; Castello, G. Serum cytokine levels as putative prognostic markers in the progression of chronic HCV hepatitis to cirrhosis. Eur. Cytokine Netw. 2010, 21, 251-256.
34. Capone, F.; Costantini, S.; Guerriero, E.; Calemma, R.; Napolitano, M.; Scala, S.; Izzo, F.; Castello, G. Serum cytokine levels in patients with hepatocellular carcinoma. Eur. Cytokine Netw. 2010, 21, 99-104.
35. Akiba, J.; Yano, H.; Ogasawara, S.; Higaki, K.; Kojiro, M. Expression and function of interleukin-8 in human hepatocellular carcinoma. Int. J. Oncol. 2001, 18, 257-264.
36. Kubo, F.; Ueno, S.; Hiwatashi, K.; Sakoda, M.; Kawaida, K.; Nuruki, K.; Aikou, T. Interleukin 8 in human hepatocellular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis. Ann. Surg. Oncol. 2005, 12, 800-807.
37. Kolls, J.K.; Linden, A. Interleukin-17 family members and infiammation. Immunity 2004, 21, 467-476.
38. Feurino, L.W.; Zhang, Y.; Bharadwaj, U.; Zhang, R.; Li, F.; Fisher, W.E.; Brunicardi, F.C.; Chen, C.; Yao, Q.; Min, L. IL-6 stimulates Th2 type cytokine secretion and upregulates VEGF and NRP-1 expression in pancreatic cancer cells. Cancer Biol. Ther. 2007, 6, 1096-1100.
39. Pei, Z.; Li, H.; Guo, Y.; Jin, Y.; Lin, D. Sodium selenite inhibits the expression of VEGF TGFbeta(1) and IL-6 induced by LPS in human PC3 cells via TLR4-NF-(K)B signaling blockage. Int. Immunopharmacol. 2010, 10, 50-56.
40. Guerriero, E.; Sorice, A.; Capone, F.; Costantini, S.; Palladino, P.; D'ischia, M.; Castello, G. Effects of Lipoic Acid Caffeic Acid and a Synthesized Lipoyl-Caffeic Conjugate on Human Hepatoma Cell Lines. Molecules 2011, 16, 6365-6377.
41. Lee, D.; Kim, J.W.; Seo, T.; Hwang, S.G.; Choi, E.J.; Choe, J. SWI/SNF complex interacts with tumor suppressor p53 and is necessary for the activation of p53-mediated transcription. J. Biol. Chem. 2002, 277, 22330-22337.
42. Copeland, P.R.; Fletcher, J.E.; Carlson, B.A.; Hatfield, D.L.; Driscoll, D.M. A novel RNA binding protein, SBP2, is required for the translation of mammalian selenoprotein mRNAs. EMBO J. 2000, 19, 306-314.
43. Burgler, S.; Mantel, P.Y.; Bassin, C.; Ouaked, N.; Akdis, C.A.; Schmidt-Weber, C.B. RORC2 is Involved in T Cell Polarization through Interaction with the FOXP3 Promoter. J. Immunol. 2010, 184, 6161-6169.
44. Sharma, A.; Gautam, V.K.; Costantini, S.; Paladino, A.; Colonna, G. Interactomic and pharmacological insights on human Sirt-1. Front. Pharmacol. 2012, 2012, 40.
45. Chatterjee, A.; Mir, S.A.; Dutta, D.; Mitra, A.; Pathak, K.; Sarkar, S. Analysis of p53 and NF-κB signaling in modulating the cardiomyocyte fate during hypertrophy. J. Cell. Physiol. 2011, 226, 2543-2554.
46. Yoon, S.O.; Kim, M.M.; Park, S.J.; Kim, D.; Chung, J.; Chung, A.S. Selenite suppresses hydrogen peroxide-induced cell apoptosis through inhibition of ASK1/JNK and activation of PI3-K/Akt pathways. FASEB J. 2002, 16, 111-113.
47. O'Neill, C.F.; Hunakova, L.; Kelland, L.R. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells. Chem. Biol. Interact. 1999, 123, 11-29.
48. Halliwell, B. Free radicals and antioxidants - quo vadis? Trends Pharmacol. Sci. 2011, 32, 125-130.